Imagine a high-tech waterproof bandage that doesn't just seal a leak but actually helps the tissue grow back. It sticks to wet surfaces instantly, meaning surgeons don't have to spend time sewing it in place. It acts like a smart plug and a healing scaffold all in one.
Post-neurosurgical CSF leaks affect up to 32% of patients, leading to expensive reoperations and a €330 million annual burden on the EU. Current solutions are slow, expensive, and often fail to provide a watertight seal.
ArtiFix, a 3-in-1 bio-absorbable adhesive nanofiber patch that seals wet tissue, adheres without sutures, and promotes dural regeneration.
If you are a medical center dealing with post-surgical CSF leaks occurring in 4–32% of cases — this project developed ArtiFix that reduces leak rates to below 1%. This prevents reoperations and reduces direct procedural costs by approximately €280 per surgery.
If you are a manufacturer dealing with the limitations of expensive, slow-to-apply dural substitutes — this project developed a 3-in-1 nanofiber adhesive patch that replaces separate sealants and sutures. It opens a path into the €12.5B soft tissue repair market.
If you are a hospital administrator dealing with the €11,000 cost per patient for CSF leak complications — this project developed a sealing solution that can save a mid-sized center €2.56M per year. It reduces extended hospitalizations and infection risks.
ArtiFix is projected to reduce direct procedural costs by approximately €280 per surgery, which is about a 30% reduction, by eliminating the need for separate sealants and suturing.
The product initially targets dural repair and has the potential to expand into the broader soft tissue repair market, valued at €12.5B.
Based on available project data, the technology is developed by Nurami Medical Ltd, but specific licensing terms are not provided.
The project period runs from 2024-12-01 to 2026-05-31, with a commercial pathway starting with a soft launch in EU and US Centres of Excellence.
It replaces the current multi-step process of using dura substitute patches, liquid sealants, and sutures with a single, easy-to-apply adhesive patch.
The project is led by a single SME, Nurami Medical Ltd, based in Israel. With a 100% industry ratio and a lean structure, the company has demonstrated high capital efficiency, reaching preliminary commercialization with only 14.8M in total funding to date.
Contact Nurami Medical Ltd regarding ArtiFix clinical case studies
Contact us to explore partnership opportunities with Nurami Medical Ltd
